Trastuzumab biosimilar - Biocon/Mylan

Drug Profile

Trastuzumab biosimilar - Biocon/Mylan

Alternative Names: Bmab-200; CANMAb; Hercules; HerMyl 1401O trastuzumab; Hertraz; Myl 1401O

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Biocon
  • Developer Biocon; Mylan
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 13 Mar 2017 Mylan enters into a global license agreement with Genentech and Roche related to patents for Trastuzumab
  • 13 Mar 2017 Mylan withdraws its Inter Partes Review (IPR) challenges against two US Genentech patents (No. 6 407 213 and 6 331 415)
  • 11 Jan 2017 Biosimilar User Fee Act (BsUFA) date for Breast cancer in USA (IV) is 2017-09-03
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top